Nuvilex's Partner Austrianova Successfully Completes First Live Cell Encapsulation in New Facility

SILVER SPRING, Md., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today announced that its partner, Austrianova, successfully completed the first live cell encapsulation at Austrianova's new facility in the Thai Science Park in Bangkok, Thailand. This is an important milestone in assuring the facility is compliant with the current Good Manufacturing Practices (cGMP) and that the encapsulation of the cancer prodrug-activating cells used in the Cell-in-a-Box(R) technology platform, as part of Nuvilex's pancreatic cancer treatment, will be fully functional.

Read more...

Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs

SILVER SPRING, MD, December 16, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell solutions for the treatment of diseases, today announced a shareholder update on the Company's cancer and diabetes programs utilizing its Cell-in-a-Box® cellulose-based live cell encapsulation technology.

Read more...

Europe must ‘kick off’ a discussion on changing the pancreatic cancer landscape, says J-Matthias Löhr

Pancreatic cancer is a “medical emergency” and must be treated as such if the situation for patients is to be improved, says J-Matthias Löhr. As professor of gastroenterology and hepatology at Sweden’s Karolinska Institutet, Löhr has direct experience in tackling what has been referred to as the world’s ‘greatest oncological challenge’.

Read more...

Nuvilex Provides Update on Significance of Austrianova's cGMP Live-Cell Encapsulation Facility

SILVER SPRING, Md., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, is pleased to provide an update on the significance of its partner, Austrianova, opening a new, state-of-the-art current Good Manufacturing Practices (cGMP)-compliant live-cell encapsulation facility inside the Thailand Science Park (TSP). This facility will produce the Cell-in-a-Box(R) live-cell encapsulation product that will be the centerpiece for all of Nuvilex's treatments in human clinical trials.

Read more...

Nuvilex Announces Name Change of Subsidiary to Viridis Biotech

SILVER SPRING, MD., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), a preclinical and clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has changed the name of its subsidiary, Medical Marijuana Sciences, Inc., to Viridis Biotech, Inc.  This name change is part of Nuvilex's continuing process to make changes at Nuvilex that better reflect its role as a biotechnology company and to strengthen the Nuvilex brand.

Read more...

Nuvilex Announces the Opening of Austrianova's cGMP Live Cell Encapsulation Facility in Thailand

SILVER SPRING, MD, December 4, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Nuvilex executives joined Thailand government officials at the grand opening of Austrianova's current Good Manufacturing Practices (cGMP) live-cell encapsulation facility within the Thai Science Park (TSP) in Bangkok, Thailand. The TSP is the premier Science, Technology and Innovation hub of Thailand and home to many leading international hi-tech and bio-tech companies.

Read more...

Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments that Combine Cell-in-a-Box® and Cannabinoid-Based Medicine

SILVER SPRING, MD, December 1, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has obtained an exclusive worldwide license from Austrianova Singapore Pte Ltd to use the unique and proprietary Cell-in-a-Box® cellulose-based live cell encapsulation technology in combination with compounds, known as cannabinoids, obtained from constituents of Cannabis for the development of disease treatments. Nuvilex's initial efforts will be directed toward developing treatments for deadly and difficult-to-treat forms of cancer.   

Read more...

Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes

SILVER SPRING, Md., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that it has formed a "Diabetes Consortium" that will be tasked with the development of Nuvilex's treatment for insulin-dependent diabetes.

Read more...

Nuvilex Executives in Southeast Asia To Further Advance Cell-in-a-Box Technology®

SILVER SPRING, MD, November 21, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today Nuvilex's Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will develop a treatment for insulin dependent diabetes, to negotiate an additional worldwide, exclusive license to use Cell-in-a-Box® live cell encapsulation with cannabinoids to treat diseases and related symptoms and to tour the new facilities of Austrianova in Singapore. Mr. Waggoner and Dr. Crabtree will also be attending the grand opening of the cGMP (current Good Manufacturing Practices) facility in Thailand where the cells required for Nuvilex's preclinical and clinical trials will be encapsulated using the Cell-in-a-Box® technology.

Read more...

Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation

SILVER SPRING, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.

Read more...